Ad Header



The Pulse of the Pharmaceutical Industry

Prostate cancer drug clears late-stage trial

Written by: | | Dated: Thursday, September 14th, 2017


Pfizer, Astellas prostate cancer drug clears late-stage trial


(Reuters) – Pfizer Inc and Astellas Pharma Inc said on Thursday their drug to treat a type of prostate cancer met the main goal of improving overall survival in a late-stage trial.

The oral drug, Xtandi, in combination with an anti-hormone therapy was more successful than an anti-hormone therapy alone in improving overall survival in men with non-metastatic castration-resistant prostate cancer.

The drug is already approved to treat metastatic castration-resistant prostate cancer.


Reporting by Tamara Mathias in Bengaluru; Editing by Savio D’Souza


Reuters source:


Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

February 2018 Focus: Top 10 Pipelines, Focused Value in Pharma, Agenda 2018 and MAHF!


Ad Right Bottom

Main Navigation